This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -25.37% and 5.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
by Zacks Equity Research
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
Esperion's Drugs in Review Hold Potential, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -8.06% and 5.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
A Firm's First Profit Can Mean Big Returns for Investors
by Benjamin Rains
We are already roughly halfway through second-quarter 2019 earnings season. This means now could be a great time to look at a 'First Profit' stock screen.
Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 132.58% and 53.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4
by Zacks Equity Research
Esperion Therapeutics (ESPR) generates no revenues in the fourth quarter. The company provides guidance for 2019.
Do Options Traders Know Something About Esperion (ESPR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
Do Options Traders Know Something About Esperion (ESPR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol
by Zacks Equity Research
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock?
by Zacks Equity Research
Investors in Esperion (ESPR) need to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Esperion Therapeutics (ESPR) Stock
by Zacks Equity Research
Investors in Esperion Therapeutics (ESPR) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Esperion (ESPR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Esperion (ESPR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
Perrigo Company (PRGO) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) Rx segment is likely to continue hurting the company's performance. However, product acquisitions and new product launches in the same might boost sales in the coming quarters.
Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings?
by Zacks Equity Research
Esperion Therapeutics (ESPR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
What's in Store for Intrexon (XON) in this Earnings Season?
by Zacks Equity Research
Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.